Genesis Genetics

genesisgenetics.org

Genesis Genetics is the leading global provider of Preimplantation Genetic Diagnosis (PGD) & Preimplantation Genetic Screening (PGS) - providing expert laboratory services for many of the most respected in vitro fertilization (IVF) centers across the country and throughout the world. Founded by a group of world-renowned scientists, Genesis Genetics has pioneered the clinical practice of preimplantation testing of embryos for inherited genetic abnormalities, and our doctors and scientists have performed many of the first and continually successful cases in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

news image

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

news image

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More

BON NATURAL LIFE LIMITED INTRODUCES NEW POWDER DRINK FOR ANTI-H. PYLORI AND DIGESTIVE HEALTH

Bon Natural | June 17, 2022

news image

Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has launched a new cruciferous vegetable based probiotic powder drink that could potentially inhibit the proliferation of Helicobacter pylori and help regulate the digestive system. The powder drink is the first proprietary product of BON's cruciferous vegetable based health supp...

Read More

Cell and Gene Therapy, Industrial Impact

SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF SC291 IND APPLICATION

Sana Biotechnology | January 30, 2023

news image

Sana Biotechnology, Inc., a firm focused on producing and delivering engineered cells as medicines, recently announced that the FDA has approved the company's Investigational New Drug (IND) application to begin a first-in-human trial of SC291 in patients with different types of B-cell malignancies. SC291 is an allogeneic CAR T cell therapy that targets CD19. It is developed by Sana using its hypoimmune platform. The hypoimmune platform's objective is to overcome the allo...

Read More
news image

MedTech

BENCHLING IS EXPANDING INTO THE EARLY DEVELOPMENT MARKET TO ACCELERATE THE CREATION OF BREAKTHROUGH PRODUCTS

Benchling | September 17, 2021

Benchling , innovator of the research and development (R&D) cloud for the biotechnology industry, today announced its entry into the early development market. The company brings new solutions to market that enable scientists for the first time to work seamlessly from research to development in a single system. By expanding the range of services, the Benchling R&D cloud is designed to offer both the flexibility and speed required for research efficiency as well as the control and conformi...

Read More
news image

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More
news image

BON NATURAL LIFE LIMITED INTRODUCES NEW POWDER DRINK FOR ANTI-H. PYLORI AND DIGESTIVE HEALTH

Bon Natural | June 17, 2022

Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has launched a new cruciferous vegetable based probiotic powder drink that could potentially inhibit the proliferation of Helicobacter pylori and help regulate the digestive system. The powder drink is the first proprietary product of BON's cruciferous vegetable based health supp...

Read More
news image

Cell and Gene Therapy, Industrial Impact

SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF SC291 IND APPLICATION

Sana Biotechnology | January 30, 2023

Sana Biotechnology, Inc., a firm focused on producing and delivering engineered cells as medicines, recently announced that the FDA has approved the company's Investigational New Drug (IND) application to begin a first-in-human trial of SC291 in patients with different types of B-cell malignancies. SC291 is an allogeneic CAR T cell therapy that targets CD19. It is developed by Sana using its hypoimmune platform. The hypoimmune platform's objective is to overcome the allo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us